Inovio Pharmaceuticals, Inc. (INO)

$11.32

+0.37

(+3.38%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $11.01
    $12.25
    $11.32
    downward going graph

    2.74%

    Downside

    Day's Volatility :10.12%

    Upside

    7.59%

    downward going graph
  • $3.89
    $14.75
    $11.32
    downward going graph

    65.64%

    Downside

    52 Weeks Volatility :73.63%

    Upside

    23.25%

    downward going graph

Returns

PeriodInovio Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
3.6%
6.5%
0.0%
6 Months
78.05%
7.1%
0.0%
1 Year
77.12%
9.8%
0.0%
3 Years
-88.98%
14.2%
-20.2%

Highlights

Market Capitalization
283.7M
Book Value
$4.04
Earnings Per Share (EPS)
-5.51
PEG Ratio
0.0
Wall Street Target Price
18.92
Profit Margin
0.0%
Operating Margin TTM
-17022.04%
Return On Assets TTM
-38.56%
Return On Equity TTM
-85.09%
Revenue TTM
717.1K
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-17.7%
Gross Profit TTM
-177.4M
EBITDA
-119.7M
Diluted Eps TTM
-5.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.42
EPS Estimate Next Year
-3.21
EPS Estimate Current Quarter
-1.0
EPS Estimate Next Quarter
-0.96

Analyst Recommendation

Buy
    55%Buy
    44%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Inovio Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
4
4
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 67.14%

Current $11.32
Target $18.92

Technicals Summary

Sell

Neutral

Buy

Inovio Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
40.2%
78.05%
77.12%
-88.98%
-67.18%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
NA
NA
0.0
-4.42
-0.85
-0.39
NA
4.04
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Buy
$283.7M
-67.18%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Inovio Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 388.44K → 102.65K (in $), with an average decrease of 73.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -25.00M → -30.46M (in $), with an average decrease of 21.9% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 275.5%

Institutional Holdings

  • Vanguard Group Inc

    6.15%

  • Renaissance Technologies Corp

    1.74%

  • BlackRock Inc

    1.31%

  • Millennium Management LLC

    1.03%

  • Geode Capital Management, LLC

    0.97%

  • Susquehanna Fundamental Investments, LLC

    0.41%

Company Information

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Organization
Inovio Pharmaceuticals, Inc.
Employees
122
CEO
Dr. Jacqueline E. Shea Ph.D.
Industry
Health Technology

Discover More

FAQs